Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 67.2% in April

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 62,600 shares, a drop of 67.2% from the March 31st total of 190,800 shares. Based on an average daily volume of 461,600 shares, the short-interest ratio is currently 0.1 days.

Provectus Biopharmaceuticals Stock Up 1.2 %

OTCMKTS:PVCT traded up $0.00 during mid-day trading on Thursday, reaching $0.20. 251,000 shares of the company’s stock traded hands, compared to its average volume of 289,478. Provectus Biopharmaceuticals has a 12-month low of $0.06 and a 12-month high of $0.22. The company has a 50 day moving average price of $0.18 and a 200-day moving average price of $0.13.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.